• ATRIVA Therapeutics

    First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including COVID-19 and influenza.


    Great potential against a wide range of respiratory viruses due to antiviral and immunomodulating activity of ATRIVA’s lead product ATR-002. Phase II RESPIRE study to evaluate efficacy in hospitalized COVID-19 patients started in early 2021 (NCT04776044). Start of Phase II in influenza is planned later in 2021.


    Learn more


  • ATRIVA Therapeutics

    Invest in research to contribute to pandemic preparedness!


    We invite you to explore our approach and development milestones presented on this website and encourage you to contact us directly.


    Get in touch


  • 1
  • 2
  • ATRIVA Therapeutics

    First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including COVID-19 and influenza.


    Learn more


  • ATRIVA Therapeutics

    Invest in research to contribute to pandemic preparedness!


    Get in touch
  • 1
  • 2

About Us

Learn more about the team behind
ATRIVA Therapeutics GmbH.

 

Read more

The ATRIVA Approach

Novel host-targeting approach to prevent viral replication.

 

Read more

Markets & Investors

Financing and business development
opportunities.

 

Read more

Press Releases

 

Read more

Media Coverage

 

Read more

Events & Presentations

 

Read more

    Contact Form

    Please, enter your name
    Please, enter your phone number
    Please, enter your e-mail address Mail address is not not valid
    Please, enter your message

    Address

    Atriva Therapeutics GmbH
    Eisenbahnstr. 1, 72072 Tübingen

    +49 (0)7071 8597673
    info@atriva-therapeutics.com

    LinkedIn
    Twitter

    In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.